Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release

2025-09-19 17:35:33 ET

The last time I wrote about Xencor ( XNCR ), it was with respect to a Seeking Alpha article entitled " Xencor: Plamotamab NHL Data Leads To RA Program Advancement ." With respect to this article, I noted the opportunity that the company had in developing the use of its bispecific CD20 X CD3 antibody for the treatment of patients with rheumatoid arthritis [RA]. This program is moving forward in a phase 1b/2a study as of the latest progress. What I also had the last time around was a "Strong Buy" rating on this company on the basis of advancing its pipeline full of bispecific antibodies for various disorders. I am still going to keep this rating on this stock for now because the company continues to make progress in terms of advancing several different types of XmAb antibodies. XmAb942 is a potent, extended half-life anti-TL1A antibody being developed to target patients with inflammatory disorders....

Read the full article on Seeking Alpha

For further details see: